Stockreport

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Werewolf Therapeutics, Inc.  (HOWL) 
PDF –  Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first half of 2024  – –  WTX-124 recomm [Read more]